380 Preliminary results of an ongoing phase I trial of FT500, a first-in-class, off-the-shelf, induced pluripotent stem cell (iPSC) derived natural killer (NK) cell therapy in advanced solid tumors

• Sarah Cooley,
• Sandip Patel,
• Kimberly Musni,
• Marlisa Anderson,
• Wayne Chu

Affiliations

Sarah Cooley

Aff1 grid.17635.360000000419368657Blood and Marrow Transplant ProgramUniversity of Minnesota Medical School Minneapolis MN USA

Sandip Patel

3University of California at San Diego, La Jolla, California, USA

Kimberly Musni

4Fate Therapeutics, Inc, San Diego, CA, USA

Marlisa Anderson

4Fate Therapeutics, Inc, San Diego, CA, USA

Wayne Chu

4Fate Therapeutics, Inc, San Diego, CA, USA